Theravance (THRX) Reports Better-Than-Expected Q1 Loss of $0.31
More News related to THRX
- Theravance and Astellas Announce the Commercial Launch of VIBATIV(TM) (telavancin) in the United States
- Theravance to Present at the 18th Annual Credit Suisse Health Care Conference
- Theravance Announces New Employment Inducement Award
- Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections in Europe
- Theravance (THRX) Posts Q3 Loss of $0.35; Revs Light
Theravance Inc. (Nasdaq: THRX) reports Q1 loss of $0.31, 1 cent better than the analyst estimate of ($0.32). Revenue for the quarter was $9.5 million, versus the consensus of $7.6 million.
Related Categories
EarningsStocks Mentioned
+0.15Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
